

Product Data Sheet

Product Name: Cridanimod

Cat. No.: GC38648

Chemical Properties

Cas. No. 38609-97-1

SMILES O=C(O)CN(C1=C2C=CC=C1)C3=CC=CC=C3C2=O


Formula $C_{15}H_{11}NO_3$ M.Wt 253.26

Solubility DMSO: 125 mg/mL (493.56 mM); Storage Store at -20°C
Water: < 0.1 mg/mL (insoluble)

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure



Background

Cridanimod is a small-molecule immunomodulator and interferon inducer[1]. Cridanimod is a potent progesterone receptor (PR) activator mediated through induction of IFN α and IFN β expression[2].

Cridanimod (IM; 1-6 mg; twice a week) has a significantly longer survival time. Cridanimod significantly increases in IFN α and - β in cridanimod-treated mice in a dose-dependent manner[1]. Animal Model: Athymic mice with hec50co cells[1]

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

[1]. Xenetic Biosciences Announces FDA Acceptance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of Virexxa® in Endometrial Cancer. AUGUST 19, 2016 [2]. Matthew J. Carlson, et al. Cridanimod and progestin therapy in hormone-resistant endometrial cancer. Journal of Clinical Oncology, January 30, 2017.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA